Extrapyramidal symptoms - Causes, Treatment & When to See a Doctor

```html

What is Extrapyramidal Symptoms?

Extrapyramidal symptoms (EPS) refer to a group of movement‑related side effects that arise when the brain’s extrapyramidal system – the network of nerve pathways that control involuntary motor functions – is disrupted. The condition is most commonly seen after exposure to certain medications, especially antipsychotics and some anti‑nausea drugs, but it can also result from neurological diseases.

EPS may range from mild, transient tremors to severe, disabling rigidity or involuntary muscle contractions. Because these symptoms can mimic neurological disorders such as Parkinson’s disease, recognizing them early is crucial for appropriate management.

Common Causes

While drug‑induced EPS is the most frequent cause, several other conditions can affect the extrapyramidal system.

• Typical (first‑generation) antipsychotics: haloperidol, chlorpromazine, fluphenazine.
• Atypical (second‑generation) antipsychotics: risperidone, olanzapine, quetiapine (especially at high doses).
• Metoclopramide and other dopamine‑blocking anti‑emetics.
• Selective serotonin reuptake inhibitors (SSRIs) and other antidepressants – rarely, especially when combined with antipsychotics.
• Antiepileptic drugs: carbamazepine, phenytoin (high doses).
• Neurological diseases: Parkinson’s disease, Huntington’s disease, Wilson’s disease.
• Neurodegenerative disorders: multiple system atrophy, progressive supranuclear palsy.
• Metabolic disturbances: severe electrolyte imbalance, hepatic encephalopathy.
• Infections: encephalitis, HIV‑related neurocognitive disorder.
• Traumatic brain injury or stroke affecting basal ganglia.

Associated Symptoms

EPS usually presents with a cluster of motor and, occasionally, non‑motor signs. Commonly co‑occurring features include:

• Dystonia: painful, sustained muscle contractions causing abnormal postures (e.g., torticollis, oculogyric crisis).
• Akathisia: an inner sense of restlessness that forces the patient to pace, shift weight, or fidget.
• Parkinsonism: bradykinesia, rigidity, resting tremor, and shuffling gait.
• Tardive dyskinesia: repetitive, involuntary movements (often of the face, lips, tongue) that may persist after the offending drug is stopped.
• Severe muscle spasms or “sialorrhea” (excessive drooling).
• Psychiatric overlay: anxiety, agitation, or depression due to discomfort.

When to See a Doctor

EPS can progress quickly and become disabling. Seek professional help if you notice any of the following:

• New or worsening muscle stiffness, tremor, or restlessness within days to weeks after starting or changing a medication.
• Severe neck or facial muscle spasms that limit movement.
• Involuntary lip‑licking, chewing, or tongue thrusting (possible tardive dyskinesia).
• Persistent gait changes, difficulty walking, or frequent falls.
• Any symptom that interferes with daily activities or causes significant distress.

Prompt evaluation can prevent long‑term disability, especially for tardive dyskinesia, which may become irreversible.

Diagnosis

Diagnosing EPS involves a combination of clinical assessment, medication review, and, when needed, ancillary tests.

1. Detailed History

• Medication list (including over‑the‑counter and herbal supplements).
• Duration and dosage of exposure.
• Temporal relationship between drug initiation and symptom onset.
• Past psychiatric or neurological disorders.

2. Physical & Neurological Examination

• Assessment of rigidity, tremor, gait, and posture.
• Standardized rating scales:
  • Simpson‑Angus Scale for Parkinsonism.
  • Barnes Akathisia Rating Scale.
  • AIMS (Abnormal Involuntary Movement Scale) for tardive dyskinesia.

3. Laboratory Tests (to rule out mimics)

• Complete blood count and metabolic panel.
• Liver function tests (especially when antipsychotics are metabolized hepatically).
• Serum copper and ceruloplasmin if Wilson’s disease is suspected.

4. Imaging (rarely required)

• Brain MRI or CT if structural lesions, stroke, or traumatic injury are suspected.
• DaT‑scan (dopamine transporter imaging) can differentiate drug‑induced Parkinsonism from idiopathic Parkinson’s disease.

Treatment Options

Treatment is directed at removing or reducing the offending cause and managing the symptoms.

1. Medication Adjustments

• Switch or lower dose: Reduce the dose of the causative antipsychotic or switch to a lower‑risk agent (e.g., aripiprazole, clozapine).
• Discontinue the drug: If clinically feasible, stopping the offending medication often leads to rapid improvement, especially for acute dystonia and akathisia.

2. Anticholinergic Agents

• Benztropine (Cogentin) or Trihexyphenidyl (Artane): First‑line for acute dystonia and parkinsonism.
• Start at low doses (e.g., benztropine 0.5–1 mg PO q6‑8 h) and titrate based on response.

3. Beta‑Blockers

• Propranolol: Effective for akathisia. Typical dose 20‑40 mg PO q6‑8 h, titrated as needed.

4. Benzodiazepines

• Short‑term use of lorazepam or clonazepam can relieve severe dystonia or agitation while other agents take effect.

5. VMAT‑2 Inhibitors (for tardive dyskinesia)

• Valbenazine (Ingrezza) or Deutetrabenazine (Austedo): FDA‑approved for tardive dyskinesia; reduce involuntary movements without worsening psychosis.

6. Physical & Occupational Therapy

• Stretching, gait training, and balance exercises help restore function and prevent falls.
• Assistive devices (canes, walkers) may be needed during recovery.

7. Lifestyle & Home Measures

• Warm compresses or gentle massage for acute dystonia.
• Regular aerobic activity to improve overall motor control.
• Avoid caffeine or stimulants that may worsen tremor.

Prevention Tips

While not all EPS can be avoided, many strategies reduce risk:

• Start low, go slow: Use the lowest effective dose of antipsychotics and titrate gradually.
• Choose agents with lower EPS risk: Atypical antipsychotics such as aripiprazole, lurasidone, or ziprasidone have a more favorable profile.
• Regular monitoring: Schedule routine follow‑ups (every 2–4 weeks initially) to assess motor side effects.
• Educate patients and caregivers: Teach early signs (restlessness, tremor) so they can report promptly.
• Consider prophylactic anticholinergics: In high‑risk patients (e.g., elderly, high‑dose typical antipsychotic), a low‑dose benztropine may be started alongside the primary medication.
• Review drug interactions: Some medications (e.g., metoclopramide) can potentiate dopamine blockade when combined with antipsychotics.
• Maintain good nutrition and hydration: Electrolyte imbalances can exacerbate movement disorders.
• Screen for underlying neurological disease: Prior to initiating high‑risk drugs, assess for Parkinsonism or other basal‑ganglia disorders.

Emergency Warning Signs

If any of the following occur, seek emergency medical care (call 911 or go to the nearest ER):

• Sudden, severe neck or facial muscle spasm that blocks the airway (risk of choking).
• Rapidly worsening breathing difficulty due to chest wall rigidity.
• Uncontrollable, high‑frequency tremor causing falls or injuries.
• Confusion, fever, or autonomic instability (high heart rate, blood pressure swings) that may indicate neuroleptic malignant syndrome—a life‑threatening complication.

References

• Mayo Clinic. “Extrapyramidal side effects.” Mayo Clinic Proceedings, 2022.
• National Institute of Mental Health (NIMH). “Antipsychotic Medications and Side Effects.” 2023.
• Cleveland Clinic. “How to Manage Drug‑Induced Parkinsonism.” 2023.
• World Health Organization (WHO). “Guidelines for the Management of Tardive Dyskinesia,” 2021.
• American Psychiatric Association. “Practice Guideline for the Treatment of Patients with Schizophrenia,” 2022.

```